Treatment Algorithm for the Management of Pcnsl - Flowchart
Treatment Algorithm for the Management of Pcnsl - Flowchart Primary Central Nervous System Lymphoma Primary Central Nervous System Lymphoma
«Flowchart»

Histopathological diagnosis of PCNSL

Histopathological diagnosis of PCNSL

Histopathological diagnosis of PCNSL

<Node Text>

<Node Text>

<Node Text>

<Node Text>

<Go to node 3>

<Go to node 3>

<Go to node 3> Node 3

<Go to node 4>

<Go to node 4>

<Go to node 4> Node 4

<End Node 3>

<End Node 3>

<End Node 3>

<End Node 3>

<End Node 4>

<End Node 4>

<End Node 4>

<End Node 4>

MATRix

MATRix

MATRix

Best supportive care

Best supportive care

Best supportive care

Age – comorbidity – PS - frailty

Age – comorbidity – PS - frailty

Age – comorbidity – PS - frailty

Patients younger than 70 yr no comorbidity

Patients younger than 70 yr no comorbidity

Patients younger than 70 yr no comorbidity

Patients older than 70 yr

Patients older than 70 yr

Patients older than 70 yr

Patients ineligible for treatment or treatment refusal

Patients ineligible for treatment or treatment refusal

Patients ineligible for treatment or treatment refusal

HDC/ASCT consolidation

HDC/ASCT consolidation

HDC/ASCT consolidation

WBRT consolidation

WBRT consolidation

WBRT consolidation

Good tolerability

Good tolerability

Good tolerability

Poor tolerability
Poor mobilizers

Poor tolerability
Poor mobilizers


Poor tolerability

End

End

End

Eligible for ASCT

Eligible for ASCT

Eligible for ASCT

Not eligible for ASCT

Not eligible for ASCT

Not eligible for ASCT

WBRT

WBRT

WBRT

Eligible for HD-MTX

Eligible for HD-MTX

Eligible for HD-MTX

Not eligible for HD-MTX

Not eligible for HD-MTX

Not eligible for HD-MTX

Maintenance

Maintenance

Maintenance

HD-MTX + alkylators + rituximab

HD-MTX + alkylators + rituximab

HD-MTX + alkylators + rituximab

Maintenance

Maintenance

Maintenance

WBRT

WBRT

WBRT